AIDX
20/20 Biolabs·NASDAQ
--
--(--)
--
--(--)
AIDX fundamentals
During Q4 2025, 20/20 Biolabs (AIDX) reported revenue of 538.27K, a YoY change of 0.41%. Net income was -1.31M, a YoY change of -4.70%. Click to view the full income statement and explore the company's earnings performance.
Income Statement
Q1,2022 | Q1,2023 | Q3,2024 | Q4,2024 | Q3,2025 | Q4,2025 | TTM |
|---|
Start Date | Jan 1, 2022 | Jan 1, 2023 | Jul 1, 2024 | Oct 1, 2024 | Jul 1, 2025 | Oct 1, 2025 | -- |
End Date | Mar 31, 2022 | Mar 31, 2023 | Sep 30, 2024 | Dec 31, 2024 | Sep 30, 2025 | Dec 31, 2025 | -- |
Fiscal Year-End | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | -- |
Revenue | 4.96M -- | 419.38K -91.55% | 361.01K -- | 536.08K -- | 417.98K +15.78% | 538.27K +0.41% | -- -- |
Sales and Services Revenue | 4.96M -- | 419.38K -91.55% | -- -- | -- -- | -- -- | -- -- | -- -- |
Cost of Revenue | 2.34M -- | 417.52K -82.18% | 336.87K -- | 373.05K -- | 272.91K -18.99% | 407.86K +9.33% | -- -- |
Gross Profit | 2.62M -- | 1.86K -99.93% | -- -- | -- -- | -- -- | -- -- | -- -- |
Operating Expenses | 682.13K -- | 2.05M +199.99% | -- -- | -- -- | -- -- | -- -- | -- -- |
Selling, General and Administrative Expenses | 656.31K -- | 1.93M +194.18% | -- -- | -- -- | -- -- | -- -- | -- -- |
Research and Development Expenses | 25.82K -- | 115.53K +347.42% | -- -- | -- -- | -- -- | -- -- | -- -- |
Operating Income | 1.94M -- | -2.04M -205.52% | -- -- | -- -- | -- -- | -- -- | -- -- |
Non-Operating Income (Loss) | 11.82K -- | 49.62K +319.68% | -- -- | -- -- | -- -- | -- -- | -- -- |
Other Non-Operating Income (Loss) | 13.63K -- | -3.23K -123.68% | -- -- | -- -- | -- -- | -- -- | -- -- |
Net Interest Expense | 1.81K -- | -52.84K -3019.50% | -- -- | -- -- | -- -- | -- -- | -- -- |
Interest Expense | 2.78K -- | 7.15K +156.81% | -- -- | -- -- | -- -- | -- -- | -- -- |
Interest Income | 973 -- | 59.99K +6065.47% | -- -- | -- -- | -- -- | -- -- | -- -- |
Pretax Income From Continuing Operations | 1.95M -- | -1.99M -202.33% | -1.87M -- | -1.25M -- | -825.54K +55.94% | -1.31M -4.70% | -- -- |
Net Income | 1.95M -- | -1.99M -202.33% | -1.87M -- | -1.25M -- | -825.54K +55.94% | -1.31M -4.70% | -- -- |
Net Income Attributable to Owners of the Company | 1.95M -- | -1.99M -202.33% | -- -- | -- -- | -- -- | -- -- | -- -- |
Net Income Attributable to Common Stockholders | 1.95M -- | -1.99M -202.33% | -- -- | -- -- | -- -- | -- -- | -- -- |
Basic EPS | 0.41 -- | -0.42 -202.44% | -0.9 -- | -- -- | -0.5 +44.44% | -- -- | -- -- |
Basic EPS from Continuing Operations | 0.41 -- | -0.42 -202.44% | -- -- | -- -- | -- -- | -- -- | -- -- |
Diluted EPS | 0.21 -- | -0.42 -300.00% | -0.9 -- | -- -- | -0.5 +44.44% | -- -- | -- -- |
Diluted EPS from Continuing Operations | 0.21 -- | -0.42 -300.00% | -- -- | -- -- | -- -- | -- -- | -- -- |
You can ask Aime
What guidance did 20/20 Biolabs's management provide for the next earnings period?What is the revenue and EPS growth rate for 20/20 Biolabs year over year?What is 20/20 Biolabs's gross profit margin?What is 20/20 Biolabs's latest dividend and current dividend yield?What does 20/20 Biolabs do and what are its main business segments?What were the key takeaways from 20/20 Biolabs’s earnings call?What is the market's earnings forecast for 20/20 Biolabs next quarter?What factors drove the changes in 20/20 Biolabs's revenue and profit?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
